DYNE THERAPEUTICS INC (DYN)
US26818M1080 - Common Stock
DYNE THERAPEUTICS INC
NASDAQ:DYN (1/14/2025, 8:00:01 PM)
After market: 15 0 (0%)15
-0.29 (-1.9%)
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 173 full-time employees. The company went IPO on 2020-09-17. The company is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. The company is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. The company also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Company Info
DYNE THERAPEUTICS INC
1560 Trapelo Road
Waltham MASSACHUSETTS 02451
P: 17817868230
CEO: Joshua Brumm
Employees: 152
Website: https://dyne-tx.com/
DYN News
5 days ago - Market News VideoDyne Therapeutics is Now Oversold (DYN)5 days ago - Dyne Therapeutics, Inc.Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for5 days ago - Dyne Therapeutics, Inc.Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study...
6 days ago - Dyne Therapeutics, Inc.Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference6 days ago - Dyne Therapeutics, Inc.Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on...
7 days ago - Dyne Therapeutics, Inc.Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ETDYN Twits
Here you can normally see the latest stock twits on DYN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
